Erik Faber MD PhD

Finally published! Thanks to all the co-authors for their monumental efforts and the reviewers who helped make this story better. Of all the science I've done to date, I'm the most proud of this. #medchem #allosteric 1/2

#GPCR remain a major target of small molecules, and this review rightly demonstrates the promise of drugging adhesion GPCRs. This could be especially impt in cancer, where we now appreciate the #TME, #ECM, integrin signaling, mechanotransduction, etc. nature.com/articles/s4157…

pubs.acs.org/doi/10.1021/ac… As a former #peptide chemist turned small mol chemist, I know this took tons of work. Lessons learned re: peptides: - ⬆️Lipophilic = better always, generally - PPB may be key - PK = major issue Also SPR exp w/ cyclins...would love to know the method

1/n Now published in @NatureMedicine : The phase 2 #POLAR trial of pembrolizumab + olaparib maintenance in metastatic pancreatic cancer. @CpcrMsk @MSKCancerCenter @MSK_DeptOfMed @PICIatMSK rdcu.be/e9WmJ

Work like this further convinces me the #ECM is more than a scaffold - it is a signal cell.com/cell/fulltext/…

Thrilled to welcome the next generation of Oslerian physicians— a group dedicated to the pursuit of excellence, to becoming master clinicians & growing through rigor, and to being leaders in medicine! welcome to the Osler Medical Residency & the Osler family! #oslerpride

Also thrilled to share the future leaders of the Osler Resideny—our 2027-2028 ACSs! @maxmcgredy @jackbuyske @mahamkaratela @Liam_P_Coyne @helminthhenry . Our ACSs are the heart of the program & embody our mission and values. We are in great hands with these 5 amazing people!

I can't tell you how many surgeries I've been in where we've debated for quite some time if a structure was vessel or nerve... Really cool #medchem work that I think has translational potential pubs.acs.org/doi/10.1021/ac…

Obesity and Cancer: A Translational Science Review jamanetwork.com/journals/jama/… "Overweight and obesity account for approximately 10% of new cancer diagnoses annually in the US and up to 50% of certain cancers such as endometrial and hepatobiliary cancer" @Neil_Iyengar

My day a day: when statistical significance flirts harder than clinical relevance

Nice review of #KRAS inhibitors: sciencedirect.com/science/articl… Interesting that MRTX1133 development halted due to PK - with improved pre-clin testing, PK issues rarely lead to failure in trials And KRAS amp seems to be major mech. of resistance - how can we exploit/prevent this?

Just in: Good news for the myeloma field. FDA approves teclistamab plus daratumumab (Tec-Dara) combination for myeloma for patients who have had at least one prior line of therapy. Note: Always use Tec-Dara with monthly IVIG. It’s not optional. That was fast! And this is unprecedented curve is why.

Big news in Cholangiocarcinoma, an aggressive GI cancer with limited tx options and rapid functional decline. In a 🇨🇳 trial, neoadj GOLP (gemcitabine, oxaliplatin, lenvatinib, toripalimab)- surgery and adj capecitabine improved EFS, with trend favoring OS (NS) nejm.org/doi/full/10.10…

2/2: Unfortunately I couldn't find the #SPR Kd data and methods - would be important to know how cyclin was able to be stable in its isolated form for such measurements, given the notorious aqueous instability of lone cyclins without their binding partners

1/2: I'm not too old but I never thought I'd see a believable #cyclin-targeting drug in my lifetime. Kudos to the effort it took to make this peptide look more like a small molecule and we'll see what happens in the clinic. pubs.acs.org/doi/10.1021/ac…

@BReinfeld Hey - only in treatment refractory settings for now

@fabermdphd What about in the setting of orthopedic injuries?!?

Is CAR-T the future for the treatment of refractory debilitating rheumatological disease? I think so We'll see if the lower toxicity in this population (no ICANS, lower grade CRS) persists with larger studies nature.com/articles/s4159…

Dual-degree training shapes application strategy, interview yield, specialty choice, and matched program characteristics. Read more: insight.jci.org/articles/view/… #MedEd #ResidencyMatch #MatchDay @A_P_S_A @JCI_Insight

I find these conclusions very believable - it should make us all think about we can remain accessible to other team members while maintaining boundaries, and the role of secure chat. And of course, we should always be working to affect systemic change rdcu.be/e43kQ

Much of combatting future human disease will require a keen focus on the liver. Work like this to develop better #organoid models will be key- e.g. what could be recapitulated/uncovered with the addition of cancer cells to these sorts of models? nature.com/articles/s4158…

Love this kind of work that connects conformational selectivity of a drug to its target with possibly improved therapeutic properties #medchem nature.com/articles/s4158…